The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...
There’s trouble brewing beneath the GLP-1 buzz. As Americans embrace blockbuster weight-loss drugs like Ozempic and Wegovy in ...
Zacks Investment Research on MSN
NVO down 42% year to date: Is this an indication to sell the stock?
Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...
A cardiologist's assertion that Ozempic is a "cardiometabolic medicine" rather than just a weight-loss trend has sparked ...
Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...
Danish pharma major Novo Nordisk has announced the launch of Ozempic (injectable semaglutide) in India. The popular ...
Weight-loss jabs, such as Ozempic and Wegovy, have revolutionised the way we treat obesity in humans, and scientists now want ...
The managing director of Novo Nordisk India on Ozempic’s delayed launch in India, leading the fight against diabetes and ...
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...
The executives of the companies say by pairing weight-loss drugs such as semaglutide (Wegovy) and tirzepatide (Mounjaro) with ...
Fondazione Telethon ETS' Waskyra has become the first gene therapy in the US for patients with Wiskott-Aldrich syndrome (WAS) ...
For Elizabeth Honigsberg, a general and bariatric surgeon and obesity and weight management specialist at Dartmouth Hitchcock Medical Center in Lebanon, combating obesity and the misconceptions that s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback